Biotech | February 05, 2021
Biocon Biologics to offer its oncology biosimilars in 30+ countries
The partnership is a significant step in delivering advanced cancer therapies to patients.
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
In his new role, Karthik will lead human capital strategy and HR operations across these regions
Former Global Head of IT & Digital Transformation at Biocon Biologics steps into enterprise-wide technology leadership role
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated
